Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

10 de setembro de 2016 atualizado por: Hoffmann-La Roche

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

991

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Alemanha
      • Aschaffenburg, Alemanha, 63739
      • Berlin, Alemanha, 10367
      • Berlin, Alemanha, 13125
      • Berlin, Alemanha, 4169
      • Bonn, Alemanha, 53113
      • Dortmund, Alemanha, 44137
      • Freiburg, Alemanha, 79106
      • Fuerstenwalde, Alemanha, 15517
      • Hamburg, Alemanha, 20357
      • Karlsruhe, Alemanha, 76135
      • Kiel, Alemanha, 24105
      • Offenbach, Alemanha, 63069
      • Stralsund, Alemanha, 18435
  • Brasil
      • Belo Horizonte, Brasil, 30150-281
      • Curitiba, Brasil, 80530-010
      • Goiania, Brasil, 74605-070
      • Itajai, Brasil, 88301-220
      • JAU, Brasil, 17210-080
      • Joao Pessoa, Brasil, 58040280
      • Porto Alegre, Brasil, 90610-000
      • Porto Alegre, Brasil, 91350-200
      • Porto Alegre, Brasil, 90430-090
      • Porto Alegre - Rs, Brasil, 90050-170
      • Rio de Janeiro, Brasil, 20560-120
      • Rio de Janeiro, Brasil, 22260-020
      • Santo Andre, Brasil, 09060-870
      • Sao Paulo, Brasil, 1323020
      • Sao Paulo, Brasil, 01317-000
  • Bulgária
      • Plovdiv, Bulgária, 4000
      • Sofia, Bulgária, 1756
      • Sofia, Bulgária, 1784
      • Varna, Bulgária, 9002
  • Bósnia e Herzegovina
      • Banja Luka, Bósnia e Herzegovina, 78000
      • Sarajewo, Bósnia e Herzegovina, 71000
  • Canadá
    • Alberta
      • Calgary, Alberta, Canadá, T2N 4N2
      • Edmonton, Alberta, Canadá, T6G 1Z2
    • British Columbia
      • Kelowna, British Columbia, Canadá, V1Y 5L3
      • Vancouver, British Columbia, Canadá, V5Z 1H5
    • Nova Scotia
      • Halifax, Nova Scotia, Canadá, B3H 2Y9
    • Ontario
      • Ottawa, Ontario, Canadá, K1H 8L6
      • Sudbury, Ontario, Canadá, J9P 3Y1
      • Toronto, Ontario, Canadá, M4N 3M5
    • Quebec
      • Greenfield Park, Quebec, Canadá, J4V 2H1
      • Montreal, Quebec, Canadá, H1T 2M4
      • Montreal, Quebec, Canadá, H3T 1E2
      • Montreal, Quebec, Canadá, H2W 1T8
  • Cingapura
      • Singapore, Cingapura, 119074
      • Singapore, Cingapura, 169610
  • Colômbia
      • Bogota, Colômbia
      • Bogota, Colômbia, 49 00
      • Monteria, Colômbia
  • Dinamarca
      • Herlev, Dinamarca, 2730
      • København, Dinamarca, 2100
      • Odense, Dinamarca, 5000
  • Eslovênia
      • Ljubljana, Eslovênia, 1000
  • Espanha
      • Barcelona, Espanha, 08035
      • Córdoba, Espanha, 14004
      • Lerida, Espanha, 25198
      • Madrid, Espanha, 28046
      • Madrid, Espanha, 28041
      • Santander, Espanha, 39008
      • Sevilla, Espanha, 41013
      • Valencia, Espanha, 46009
      • Zaragoza, Espanha, 50009
  • Estados Unidos
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
      • Tucson, Arizona, Estados Unidos, 85719
    • California
      • Anaheim, California, Estados Unidos, 92801
      • Anaheim, California, Estados Unidos, 92807
      • Bakersfield, California, Estados Unidos, 93309
      • Baldwin Park, California, Estados Unidos, 91706
      • Bellflower, California, Estados Unidos, 90706
      • Duarte, California, Estados Unidos, 91010
      • Fontana, California, Estados Unidos, 92335
      • Hayward, California, Estados Unidos, 94545
      • Irvine, California, Estados Unidos, 92618
      • La Jolla, California, Estados Unidos, 92093
      • La Mesa, California, Estados Unidos, 91942
      • Loma Linda, California, Estados Unidos, 92354
      • Long Beach, California, Estados Unidos, 90806
      • Los Angeles, California, Estados Unidos, 90025
      • Los Angeles, California, Estados Unidos, 90057
      • Los Angeles, California, Estados Unidos, 90095-1772
      • Los Angeles, California, Estados Unidos, 90034
      • Montebello, California, Estados Unidos, 90640
      • Newport Beach, California, Estados Unidos, 92660
      • Oakland, California, Estados Unidos, 94611
      • Panorama City, California, Estados Unidos, 91402
      • Riverside, California, Estados Unidos, 92505
      • Roseville, California, Estados Unidos, 95661
      • Sacramento, California, Estados Unidos, 95825
      • San Diego, California, Estados Unidos, 92123
      • San Diego, California, Estados Unidos, 92120
      • San Francisco, California, Estados Unidos, 94115
      • San Jose, California, Estados Unidos, 95119
      • Santa Clara, California, Estados Unidos, 95051
      • Santa Maria, California, Estados Unidos, 93454
      • Santa Monica, California, Estados Unidos, 90404
      • South San Francisco, California, Estados Unidos, 94080
      • Thousand Oaks, California, Estados Unidos, 91360
      • Vallejo, California, Estados Unidos, 94589
      • Walnut Creek, California, Estados Unidos, 94596
      • Woodland Hills, California, Estados Unidos, 91367
    • Colorado
      • Fort Collins, Colorado, Estados Unidos, 80528
    • Connecticut
      • Norwalk, Connecticut, Estados Unidos, 06856
      • Norwich, Connecticut, Estados Unidos, 06360
      • Stamford, Connecticut, Estados Unidos, 06902
    • District of Columbia
      • Washington, District of Columbia, Estados Unidos, 20010
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33486
      • Fernandina Beach, Florida, Estados Unidos, 32034
      • Fort Myers, Florida, Estados Unidos, 33916
      • Ft. Lauderdale, Florida, Estados Unidos, 33316
      • Hollywood, Florida, Estados Unidos, 33021
      • Jacksonville, Florida, Estados Unidos, 32205
      • Jacksonville, Florida, Estados Unidos, 32256
      • Jacksonville, Florida, Estados Unidos, 32207
      • Jacksonville, Florida, Estados Unidos, 32258
      • Kissimmee, Florida, Estados Unidos, 34741
      • Lakeland, Florida, Estados Unidos, 33804-1057
      • Miami, Florida, Estados Unidos, 33136
      • Miami, Florida, Estados Unidos, 33176
      • Miami, Florida, Estados Unidos, 33133
      • Orange Park, Florida, Estados Unidos, 32073
      • Pembroke Pines, Florida, Estados Unidos, 33028
    • Georgia
      • Athens, Georgia, Estados Unidos, 30607
      • Atlanta, Georgia, Estados Unidos, 30342
      • Atlanta, Georgia, Estados Unidos, 30322
      • Atlanta, Georgia, Estados Unidos, 30341
      • Atlanta, Georgia, Estados Unidos, 30318
      • Carrolton, Georgia, Estados Unidos, 30117
      • Cartersville, Georgia, Estados Unidos, 30121
      • Decatur, Georgia, Estados Unidos, 30033
      • Douglasville, Georgia, Estados Unidos, 30134
      • Macon, Georgia, Estados Unidos, 31217
      • Marietta, Georgia, Estados Unidos, 30060
    • Idaho
      • Boise, Idaho, Estados Unidos, 83712
      • Meridian, Idaho, Estados Unidos, 83642
      • Nampa, Idaho, Estados Unidos, 83686
      • Post Falls, Idaho, Estados Unidos, 83854
      • Twin Falls, Idaho, Estados Unidos, 83301
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60612
      • Decatur, Illinois, Estados Unidos, 62526
      • Effingham, Illinois, Estados Unidos, 62526
      • Joliet, Illinois, Estados Unidos, 60435
      • Morris, Illinois, Estados Unidos, 60450
      • Peoria, Illinois, Estados Unidos, 61615-7828
      • Skokie, Illinois, Estados Unidos, 60076
      • Zion, Illinois, Estados Unidos, 60099
    • Iowa
      • Bettendorf, Iowa, Estados Unidos, 52722
    • Kansas
      • Wichita, Kansas, Estados Unidos, 67214-3728
    • Kentucky
      • Paducah, Kentucky, Estados Unidos, 42001
    • Louisiana
      • Covington, Louisiana, Estados Unidos, 70433
      • Lafayette, Louisiana, Estados Unidos, 70503
      • Marrero, Louisiana, Estados Unidos, 70072
      • Metairie, Louisiana, Estados Unidos, 70006
      • New Orleans, Louisiana, Estados Unidos, 70115
    • Maine
      • Kittery, Maine, Estados Unidos, 03904
      • Wells, Maine, Estados Unidos, 04090
      • York, Maine, Estados Unidos, 03909
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21202
      • Baltimore, Maryland, Estados Unidos, 21237
      • Bethesda, Maryland, Estados Unidos, 20817
      • Rockville, Maryland, Estados Unidos, 20850
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
      • Boston, Massachusetts, Estados Unidos, 02114
      • Boston, Massachusetts, Estados Unidos, 02118
      • Boston, Massachusetts, Estados Unidos, 02115
      • Burlington, Massachusetts, Estados Unidos, 01805
      • Peabody, Massachusetts, Estados Unidos, 01960
    • Michigan
      • Brownstown, Michigan, Estados Unidos, 48183
      • Dearborn, Michigan, Estados Unidos, 48126
      • Detroit, Michigan, Estados Unidos, 48201
      • Detroit, Michigan, Estados Unidos, 48202
      • Saint Joseph, Michigan, Estados Unidos, 49085
      • West Bloomfield, Michigan, Estados Unidos, 48322
    • Minnesota
      • Edina, Minnesota, Estados Unidos, 55414
      • Maplewood, Minnesota, Estados Unidos, 55109
      • Minneapolis, Minnesota, Estados Unidos, 55454
      • Saint Louis Park, Minnesota, Estados Unidos, 55426
      • Saint Paul, Minnesota, Estados Unidos, 55101
      • St. Louis Park, Minnesota, Estados Unidos, 55426
    • Missouri
      • Joplin, Missouri, Estados Unidos, 64804
      • Kansas City, Missouri, Estados Unidos, 64111
      • Saint Louis, Missouri, Estados Unidos, 63110
      • Saint Peters, Missouri, Estados Unidos, 63110
      • St. Louis, Missouri, Estados Unidos, 63141
      • St. Peters, Missouri, Estados Unidos, 63376
    • Montana
      • Missoula, Montana, Estados Unidos, 59802
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68114
    • Nevada
      • Henderson, Nevada, Estados Unidos, 89052
    • New Jersey
      • Cherry Hill, New Jersey, Estados Unidos, 08002
      • Hackensack, New Jersey, Estados Unidos, 07601
      • Morristown, New Jersey, Estados Unidos, 07962
      • Parsippany, New Jersey, Estados Unidos, 07054
      • Voorhees, New Jersey, Estados Unidos, 08043
    • New Mexico
      • Santa Fe, New Mexico, Estados Unidos, 87505
    • New York
      • Brockport, New York, Estados Unidos, 14420
      • Canandaigua, New York, Estados Unidos, 14424
      • Fresh Meadows, New York, Estados Unidos, 11366
      • Geneva, New York, Estados Unidos, 14456
      • Greece, New York, Estados Unidos, 14626
      • Lake Success, New York, Estados Unidos, 11042
      • Mount Kisco, New York, Estados Unidos, 10549
      • Rochester, New York, Estados Unidos, 14626
      • Stony Brook, New York, Estados Unidos, 11794
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28203
      • Durham, North Carolina, Estados Unidos, 27710
      • Hickory, North Carolina, Estados Unidos, 28602
      • Kinston, North Carolina, Estados Unidos, 28501
      • Washington, North Carolina, Estados Unidos, 27889
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
      • Cleveland, Ohio, Estados Unidos, 44106
      • Columbus, Ohio, Estados Unidos, 43215
      • Columbus, Ohio, Estados Unidos, 43219
      • Columbus, Ohio, Estados Unidos, 43228
      • Middletown, Ohio, Estados Unidos, 45042
      • Newark, Ohio, Estados Unidos, 43055
      • Sandusky, Ohio, Estados Unidos, 44870
    • Oregon
      • Portland, Oregon, Estados Unidos, 97227
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19124
      • Philadelphia, Pennsylvania, Estados Unidos, 19106
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
    • Rhode Island
      • East Providence, Rhode Island, Estados Unidos, 02915
    • South Carolina
      • Columbia, South Carolina, Estados Unidos, 29210
      • North Charleston, South Carolina, Estados Unidos, 29425
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38120
      • Nashville, Tennessee, Estados Unidos, 37203
    • Texas
      • Austin, Texas, Estados Unidos, 78731
      • Bryan, Texas, Estados Unidos, 77802
      • Cypress, Texas, Estados Unidos, 77429
      • Dallas, Texas, Estados Unidos, 75230
      • El Paso, Texas, Estados Unidos, 79902
      • Houston, Texas, Estados Unidos, 77090
      • Shenandoah, Texas, Estados Unidos, 77384
      • Temple, Texas, Estados Unidos, 76501
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
    • Washington
      • Gig Harbor, Washington, Estados Unidos, 98332
      • Lakewood, Washington, Estados Unidos, 98499
      • Puyallup, Washington, Estados Unidos, 98372
      • Tacoma, Washington, Estados Unidos, 98405
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
      • Wausau, Wisconsin, Estados Unidos, 54401
  • Federação Russa
      • Kemerovo, Federação Russa, 650036
      • Moscow, Federação Russa, 121356
      • St Petersburg, Federação Russa, 197758
  • Filipinas
      • Diliman, Quezon City, Filipinas, 1100
      • Quezon City, Luzon, Filipinas, 1101
  • Finlândia
      • Helsinki, Finlândia, 00180
      • Tampere, Finlândia, 33520
      • Turku, Finlândia, 20520
  • França
      • Avignon, França, 84082
      • Bordeaux, França, 33076
      • Brest, França, 29609
      • Caen, França, 14076
      • Dijon, França, 21079
      • La Roche Sur Yon, França, 85925
      • Montpellier, França, 34298
      • Paris, França, 75248
      • Saint Brieuc, França, 22015
      • Saint Herblain, França, 44805
      • Vandoeuvre-les-nancy, França, 54511
  • Hong Kong
      • Hong Kong, Hong Kong
  • Itália
      • Aviano, Itália, 33081
      • Bologna, Itália, 40138
      • Candiolo, Itália, 10060
      • Genova, Itália, 16132
      • Meldola, Itália, 47014
      • Milano, Itália, 20133
      • Milano, Itália, 20141
      • Napoli, Itália, 80131
      • Negrar, Itália, 37024
      • Pisa, Itália, 56100
      • Reggio Emilia, Itália, 42100
      • Roma, Itália, 00168
      • Rozzano, Itália, 20089
      • Sassari, Itália, 07100
      • Terni, Itália, 05100
  • México
      • Acapulco, México, 39670
      • Oaxaca, México, 68000
      • Toluca, México, 50180
  • Nova Zelândia
      • Newtown, Nova Zelândia, 6021
      • Palmerston North, Nova Zelândia, 4442
  • Polônia
      • Bialystok, Polônia, 15-027
      • Gdansk, Polônia, 80-952
      • Krakow, Polônia, 31-531
      • Lublin, Polônia, 20-090
      • Opole, Polônia, 45-060
      • Poznan, Polônia, 61-866
      • Warszawa, Polônia, 02-781
  • Portugal
      • Coimbra, Portugal, 3000-075
      • Lisboa, Portugal, 1649-035
      • Porto, Portugal, 4200-072
  • Reino Unido
      • Bournemouth, Reino Unido, BH7 7DW
      • Cardiff, Reino Unido, CF14 2TL
      • Denbigh, Reino Unido, LL18 5UJ
      • London, Reino Unido, SE1 7EH
      • London, Reino Unido, SW3 6JJ
      • Manchester, Reino Unido, M20 4BX
      • New Castle Upon Tyne, Reino Unido, NE7 7DN
      • Northwood, Reino Unido, HA6 2RN
      • Poole, Reino Unido, BH15 2JB
      • Preston, Reino Unido, PR2 9HT
      • Romford, Reino Unido, RM7 0AG
      • Sutton, Reino Unido, SM2 5PT
      • Weston Super Mare, Reino Unido, BS23 4TQ
  • Republica da Coréia
      • Kyunggi-do, Republica da Coréia, 411-769
      • Seoul, Republica da Coréia, 110-744
      • Seoul, Republica da Coréia, 120-752
      • Seoul, Republica da Coréia, 135-710
  • Suécia
      • Eskilstuna, Suécia, 63188
      • Gaelve, Suécia, 80187
      • Goteborg, Suécia, 40036
  • Suíça
      • Luzern, Suíça, 6004
      • St. Gallen, Suíça, 9007
  • Taiwan
      • Kaohsung, Taiwan, 883
      • Taichung, Taiwan, 404
      • Taichung, Taiwan, 407
      • Taipei, Taiwan, 112
      • Taoyuan, Taiwan, 333
  • Índia
      • Bangalore, Índia, 560027
      • Gurgaon, Índia, 122001
      • Kolkata, Índia, 700 053
      • New Delhi, Índia, 110029
      • Pune, Índia, 411004

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
  • Histologically or cytologically confirmed invasive breast cancer
  • Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent
  • Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
  • Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
  • Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment

Exclusion Criteria:

  • History of treatment with trastuzumab emtansine
  • Prior treatment with lapatinib or capecitabine
  • Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above
  • History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria
  • History of radiation therapy within 14 days of randomization
  • Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction or unstable angina within 6 months of randomization
  • Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
  • Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)
  • Pregnancy or lactation
  • Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
  • Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
  • History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
  • Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency
  • Current treatment with sorivudine or its chemically related analogs, such as brivudine

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Trastuzumab emtansine
Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
Medicamento: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Outros nomes:
  • RO5304020
  • T-DM1
  • Trastuzumabe-MCC-DM1
Comparador Ativo: Lapatinib + Capecitabine
Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
Medicamento: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Outros nomes:
  • Tykerb
  • Tyverb
Medicamento: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Outros nomes:
  • Xeloda

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants Who Died: Second Interim Analysis
Prazo: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
Prazo: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Percentage of Participants Who Died: Final Analysis
Prazo: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Overall Survival: Final Analysis
Prazo: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Percentage of Participants Who Were Alive at Year 1
Prazo: Year 1
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Year 1
Percentage of Participants Who Were Alive at Year 2
Prazo: Year 2
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Year 2

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants With PD or Death as Assessed by the Investigator
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PFS as Assessed by the Investigator
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Duration of Objective Response (DOR) as Assessed by an IRC
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Clinical Benefit as Assessed by an IRC
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Treatment Failure
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Treatment Failure
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Symptom Progression
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Symptom Progression
Prazo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Hoffmann-La Roche

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de fevereiro de 2009

Conclusão Primária (Real)

1 de julho de 2012

Conclusão do estudo (Real)

1 de setembro de 2015

Datas de inscrição no estudo

Enviado pela primeira vez

22 de janeiro de 2009

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de janeiro de 2009

Primeira postagem (Estimativa)

26 de janeiro de 2009

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

31 de outubro de 2016

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de setembro de 2016

Última verificação

1 de setembro de 2016

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • BO21977
  • TDM4370g (Outro identificador: Genentech)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Câncer de mama

Ensaios clínicos em Trastuzumab emtansine

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Canada

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever